poisar

Stocks · News reference

Formycon AG Announces Non-Cash Impairments and Revises Adjusted EBITDA Guidance

Fiscal.ai

Formycon AG is recognizing non-cash impairments on its FYB201 and FYB202 biosimilar products and has revised its adjusted EBITDA guidance for fiscal year 2026 due to increased market competition.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading